Reported 1 day ago
As the JPMorgan Healthcare Conference kicks off, industry leaders predict a rebound in healthcare mergers and acquisitions (M&A) in 2025, following a subdued year in 2024. Maurits Pot, CEO of Tema ETFs, anticipates growth particularly in oncology, neuroscience, and metabolic sectors, despite challenges in the GLP-1 market. Major companies like Eli Lilly, Johnson & Johnson, and GSK are already announcing deals, suggesting a more active market ahead.
Source: YAHOO